The price you pay for Symbicort may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. You may be able to lower your long-term costs by getting a ...
The government is taking steps to curb use of some long-acting asthma drugs taken by millions, issuing safety restrictions Thursday to lower an uncommon but potentially life-threatening risk that ...
Symbicort, which is used to treat chronic obstructive pulmonary disease and asthma, can cause side effects. Mild side effects include nasal congestion and headaches. Serious side effects include ...
The US Food and Drug Administration has approved AstraZeneca's Symbicort inhalation aerosol (80/4.5 mcg) for children aged 6 to 12 years with asthma that is not well controlled with an inhaled ...
Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain uncertain ...
Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler. Before using Symbicort, tell your healthcare provider if you have health conditions like adrenal ...
After seeing four of its patents for its Symbicort tossed aside, AstraZeneca has gained a key victory in defense of its blockbuster inhaler. A federal court in West Virginia upheld the company’s claim ...
London, UK, Thursday 23 March 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...
The U.S. Food and Drug Administration said yesterday that it has given approval for the first generic of the Symbicort inhaler to treat asthma and COPD. Symbicort is a combination of budesonide and ...
The pediatric approval was based on the results of the Phase 3 CHASE (ChildHood Asthma Safety and Efficacy) 3 trial. The Food and Drug Administration (FDA) has approved Symbicort (budesonide and ...
In the courtroom fracas over the patents on AstraZeneca’s multibillion-dollar inhaler Symbicort, Viatris and Kindeva Drug Delivery have toppled yet another intellectual property pillar. Still, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback